Health and Fitness Health and Fitness
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013
Sun, April 28, 2013
Fri, April 26, 2013
Thu, April 25, 2013
Wed, April 24, 2013
Tue, April 23, 2013
Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013

Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference


//health-fitness.news-articles.net/content/2013/ .. at-the-needham-annual-healthcare-conference.html
Published in Health and Fitness on Thursday, April 18th 2013 at 13:16 GMT by Market Wire   Print publication without navigation


April 18, 2013 16:05 ET

Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwired - Apr 18, 2013) - Sarepta Therapeutics (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Needham & Company Annual Healthcare Conference in New York, NY on Tuesday, April 30, 2013 at 4:20 p.m. Eastern Time. Chris Garabedian, Sarepta's president and CEO, will be the presenter.

The presentation will be webcast live under the investor relations section of Sarepta Therapeutics' website at [ www.sareptatherapeutics.com ] and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources